Hangzhou Sciwind Biosciences Co., Ltd. and Pfizer China announced today that they have entered into a strategic commercialization agreement for the next-generation biased GLP-1 receptor agonist, Ecnoglutide injection.

Under the terms of the agreement, Pfizer will obtain exclusive commercialization rights for the product in mainland China, marking its initial strategic step into the metabolic disease field within the Chinese market. Concurrently, Sciwind Biosciences will remain the Marketing Authorization Holder (MAH) for the licensed product, responsible for its research and development, regulatory registration, production, and supply. Sciwind Biosciences is eligible to receive payments from Pfizer totaling up to USD 495 million, which includes an upfront payment, as well as regulatory and sales milestone payments.

Ecnoglutide is a novel cAMP-biased GLP-1 receptor agonist independently developed by Sciwind Biosciences. It is designed to offer a more precise treatment option for patients with type 2 diabetes and those requiring long-term weight management. The Ecnoglutide injection received approval from the National Medical Products Administration (NMPA) in January 2026 for the treatment of adults with type 2 diabetes. Furthermore, the application for its marketing authorization for the long-term weight management indication in adults has been accepted by the NMPA.